SITC Resource Library

On March 5, 2021, leading experts in cancer immunotherapy presented an overview of the publication "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events" during a live webinar. The recorded webinar and presentation slides are available below.

Webinar Faculty:

• Moderator: Stephan Grupp, MD, PhD – Children’s Hospital of Philadelphia and University of Pennsylvania (Expert Panel Chair)
  
• Matthew J. Frigault, MD, MSc – Massachusetts General Hospital (Expert Panel Member)
  
• Frederick L. Locke, MD – Moffitt Cancer Center (Expert Panel Member)
• Bianca D. Santomasso, MD, PhD – Memorial Sloan Kettering Cancer Center (Expert Panel Member)

• SITC's cancer immunotherapy guidelines on immune effector cell-related adverse events
• Properly monitoring patients receiving immune effector cell therapies for treatment-related adverse events and identifying those at high risk
• Identifying common and uncommon toxicities that may occur with immune effector cell therapies
• Determining appropriate management techniques for common adverse events resulting from immune effector cell therapies

Disclaimer: Due to the rapidly-evolving field of cancer immunotherapy, some of the content on this page may be out of date. For current information from SITC on cancer immunotherapy, please visit connected.sitcancer.org.